Harvard Corporate Governance

JUNE 7, 2023

The circumstances surrounding gene sequence business Illumina, Inc.’s s acquisition of GRAIL, Inc. Shareholders — and governments around the world­ — had foreseeable concerns with the proposed acquisition from the get-go. more…)

222

222

Benzinga

DECEMBER 12, 2023

Illumina Inc (NASDAQ: ILMN ) reportedly clashed with EU antitrust regulators, alleging an overreach in their investigation into its $7.1 billion acquisition of Grail Inc. Full story available on Benzinga.com

Start-ups 52

Start-ups Equity Marketability 52

Law 360 M&A

OCTOBER 19, 2023

The Fifth Circuit is asking Illumina Inc. and the Federal Trade Commission how a recent European Union order that Illumina sell off cancer detection company Grail Inc. will impact the FTC's suit challenging the $8 billion purchase.

40

40

Law 360 M&A

MARCH 15, 2023

Carl Icahn on Wednesday said life sciences company Illumina Inc. is "insulting" the intelligence of its shareholders after the company defended its board and said it would not recommend Icahn's director nominees, the latest volley amid the billionaire's efforts to get Illumina to divest cancer biotech company Grail Inc.

40

40

Law 360 M&A

MARCH 23, 2023

Federal Trade Commission staffers pushed back against Illumina's contentions that enforcers improperly coordinated with overseas counterparts to try and derail its deal for cancer-testing outfit Grail Inc., saying the company wants to distract from the merits of the commission's challenge.

52

52

Benzinga

SEPTEMBER 2, 2022

Illumina Inc (NASDAQ: ILMN ) said it received a favorable initial decision from the judge overseeing the U.S. Federal Trade Commission's challenge to the Grail transaction.

Marketability 52

Marketability 52

Law 360 M&A

OCTOBER 17, 2023

Carl Icahn on Tuesday lodged a proposed securities class and derivative action against Illumina Inc. and its board of directors, accusing them of breaching their fiduciary duties to stockholders, a suit that follows Icahn's monthslong campaign against the biotech company's reacquisition of a cancer testing company.

40

40

Law 360 M&A

AUGUST 11, 2023

Illumina Inc. Securities and Exchange Commission is probing its 2020 reacquisition of Grail for $8 billion, including the conduct and pay of the companies' management. has revealed in a securities filing that the U.S.

40

40

Reynolds Holding

FEBRUARY 14, 2024

Illumina that a director was not permitted to share confidential and privileged information he received in connection with his board service with the activist stockholders that nominated him for election. Recently, the Delaware Court of Chancery held in Icahn v. despite antitrust regulatory opposition. despite antitrust regulatory opposition.

45

45

Law 360 M&A

JUNE 8, 2023

A public interest group urged the Fifth Circuit on Thursday to declare the Federal Trade Commission's structure unconstitutional in a filing supporting Illumina Inc.'s s appeal of the commission's order unwinding the DNA sequencing company's repurchase of cancer testing outfit Grail.

40

40

Law 360 M&A

MARCH 8, 2023

Illumina Inc. says the Federal Trade Commission improperly coordinated with its European counterparts to derail the company's $8 billion reacquisition of cancer-testing outfit Grail Inc. and wants documentation of the enforcers' conversations entered into the FTC's record.

40

40

Benzinga

JUNE 5, 2023

Get Ready For Apple's WWDC: Software Updates and First New Significant Product In a Decade Apple Inc (NASDAQ: AAPL ) prepares to showcase its VR headset, marking its first significant new product in nearly a decade, on Monday at its annual developer conference. megabanks with substantial trading operations.

Banking 52

Banking Marketability 52

Law 360 M&A

APRIL 13, 2023

Federal Trade Commission staffers urged the commissioners to ensure Illumina remains separate from Grail Inc. while the company appeals an order to unwind their merger, arguing that keeping their operations apart will spur competition from rival cancer tests.

40

40

Law 360 M&A

APRIL 5, 2023

Federal Trade Commission's order for Illumina Inc. to unwind its reacquisition of Grail, but said he remains concerned about the biotech company's future under CEO Francis deSouza, calling for his "immediate" removal. Activist investor Carl Icahn said Wednesday he is "not surprised" by the U.S.

40

40

Law 360 M&A

NOVEMBER 10, 2022

Biotechnology company Illumina Inc. told members of the Federal Trade Commission in a brief that the agency's in-house judge was right to reject the commission's challenge of its Grail Inc. acquisition, contending that the "lifesaving transaction" will revolutionize cancer screening.

40

40

Law 360 M&A

SEPTEMBER 6, 2022

The European Union's antitrust watchdog on Tuesday banned DNA sequencing giant Illumina's $8 billion reacquisition of medical testing company Grail Inc., indicating that it will order the companies to unwind the completed deal to protect competition for new cancer screening tests.

40

40

Law 360 M&A

SEPTEMBER 9, 2022

Europe's antitrust authority opened its doors on Friday for businesses to discuss its enhanced powers to block mergers, after it banned DNA sequencing giant Illumina's $8 billion reacquisition of Grail Inc., a medical testing company.

40

40

Law 360 M&A

MARCH 13, 2023

Activist investor Carl Icahn on Monday launched a proxy fight against Illumina Inc.,

40

40

Benzinga

OCTOBER 4, 2023

04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. The combined company, with a pro-forma equity value of over $1 billion based on Standard BioTools' closing share price on October 3, 2023, will be a leading provider of differentiated multi-omics tools for research. and BOULDER, Colo.,

Technology 40

Technology Capital Structure Equity Marketability 40

Reynolds Holding

OCTOBER 10, 2022

Illumina/GRAIL. Michael Chappell (ALJ) issued a nearly 200-page decision dismissing the FTC’s complaint against Illumina, Inc.’s s vertical acquisition of GRAIL, Inc. Illumina sells next-generation sequencing (NGS) instruments and consumables. We discuss the decisions below.

Marketability 56

Marketability Technology 56

Reynolds Holding

JANUARY 21, 2024

As we previously discussed, the new Merger Guidelines demonstrate an increased focus on vertical and conglomerate transactions, competition for labor, potential competition, transactions involving private equity and technology companies, and market trends toward concentration. In Louisiana Children’s Medical Center/HCA Healthcare, Inc.

Marketability 45

Marketability Technology Equity 45